XML 43 R17.htm IDEA: XBRL DOCUMENT
v2.4.0.8

Segment Reporting | 6 Months Ended
--- | ---
Jun. 30, 2014
Segment Reporting [Abstract] |
Segment Reporting | Segment Reporting. The Company has four reportable segments: Apex, Oxford, Physician, and Life Sciences Europe. During the quarter ended March 31, 2014, the Company underwent a realignment of the former Life Sciences segment. As a result of this realignment, Lab Support U.S. is now included in the Apex segment; Valesta U.S. is now included in the Oxford segment; and the Life Sciences Europe segment includes Lab Support Europe, Valesta Europe, and Sharpstream. During 2013, the Company sold its Nurse Travel and Allied Healthcare divisions. See Note 4 Discontinued Operations for further information. The realignment and divestitures resulted in changes to the internal reporting package reviewed by the Chief Operating Decision Maker ("CODM"), and the Healthcare segment no longer exists. Health Information Management, formerly included in the Healthcare Segment, is included in the Oxford Segment and unallocated corporate expenses are separately disclosed in order to align with the revised internal reporting package reviewed by the CODM. All prior periods have been retrospectively restated to conform to the current presentation. The Company’s management evaluates the performance of each segment primarily based on revenues, gross profit, and operating income. The information in the following table is derived directly from the segments’ internal financial reporting used for corporate management purposes. The Company's management does not evaluate, manage or measure performance of segments using asset information, and such information is not readily available. Accordingly, assets by reportable segment are not disclosed. The following tables present revenues, gross profit, operating income and amortization by reportable segment (in thousands):
| Three Months Ended June 30, 2014
| Apex |  | Oxford |  | Physician |  | Life Sciences Europe |  | Corporate |  | Total
Revenues | $ | 297,893 |  |  | $ | 126,004 |  |  | $ | 33,657 |  |  | $ | 11,064 |  |  | $ | — |  |  | $ | 468,618 |
Gross profit | 84,677 |  |  | 53,611 |  |  | 10,298 |  |  | 4,141 |  |  | — |  |  | 152,727 |
Operating income | 31,708 |  |  | 17,828 |  |  | 2,455 |  |  | 1,028 |  |  | (14,371 | ) |  | 38,648 |
Amortization | 4,089 |  |  | 1,362 |  |  | 634 |  |  | 71 |  |  | — |  |  | 6,156 |
| Three Months Ended June 30, 2013
| Apex |  | Oxford |  | Physician |  | Life Sciences Europe |  | Corporate |  | Total
Revenues | $ | 262,347 |  |  | $ | 109,153 |  |  | $ | 26,466 |  |  | $ | 9,898 |  |  | $ | — |  |  | $ | 407,864 |
Gross profit | 72,912 |  |  | 37,122 |  |  | 7,640 |  |  | 3,658 |  |  | — |  |  | 121,332 |
Operating income | 24,637 |  |  | 15,944 |  |  | 2,213 |  |  | 448 |  |  | (11,467 | ) |  | 31,775 |
Amortization | 4,881 |  |  | 96 |  |  | 176 |  |  | 102 |  |  | 20 |  |  | 5,275 |
| Six Months Ended June 30, 2014
| Apex |  | Oxford |  | Physician |  | Life Sciences Europe |  | Corporate |  | Total
Revenues | $ | 576,301 |  |  | $ | 243,504 |  |  | $ | 65,448 |  |  | $ | 22,639 |  |  | $ | — |  |  | $ | 907,892 |
Gross profit | 160,183 |  |  | 102,637 |  |  | 19,136 |  |  | 8,359 |  |  | — |  |  | 290,315 |
Operating income | 54,492 |  |  | 32,112 |  |  | 3,714 |  |  | 2,227 |  |  | (26,615 | ) |  | 65,930 |
Amortization | 8,178 |  |  | 2,732 |  |  | 1,268 |  |  | 142 |  |  | 8 |  |  | 12,328 |
| Six Months Ended June 30, 2013
| Apex |  | Oxford |  | Physician |  | Life Sciences Europe |  | Corporate |  | Total
Revenues | $ | 502,112 |  |  | $ | 211,841 |  |  | $ | 52,768 |  |  | $ | 20,187 |  |  | $ | — |  |  | $ | 786,908 |
Gross profit | 136,893 |  |  | 71,937 |  |  | 15,123 |  |  | 7,490 |  |  | — |  |  | 231,443 |
Operating income | 41,866 |  |  | 29,610 |  |  | 4,639 |  |  | 981 |  |  | (22,466 | ) |  | 54,630 |
Amortization | 9,762 |  |  | 203 |  |  | 352 |  |  | 262 |  |  | 75 |  |  | 10,654 |
The Company operates internationally, with operations mainly in the United States, Europe, Canada, Australia and New Zealand. The following table presents domestic and foreign revenues (in thousands):
| Three Months Ended |  | Six Months Ended
| June 30, |  | June 30,
| 2014 |  | 2013 |  | 2014 |  | 2013
Revenues: |  |  |  |  |  |  |
Domestic | $ | 448,296 |  |  | $ | 388,744 |  |  | $ | 866,960 |  |  | $ | 747,393 |
Foreign | 20,322 |  |  | 19,120 |  |  | 40,932 |  |  | 39,515 |
| $ | 468,618 |  |  | $ | 407,864 |  |  | $ | 907,892 |  |  | $ | 786,908 |

X
- Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 29 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8864-108599 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8933-108599 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8844-108599 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 10 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8538-108599 Reference 5: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8380-108599 Reference 6: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8981-108599 Reference 7: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 35 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8984-108599 Reference 8: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 30 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8906-108599 Reference 10: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9054-108599 Reference 11: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8924-108599 Reference 12: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e9031-108599 Reference 13: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 33 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8971-108599 Reference 14: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 12 -URI http://asc.fasb.org/extlink&oid=6534315&loc=d3e8595-108599 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration